Testing a new drug combo for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new drug combination, inobrodib plus pomalidomide and dexamethasone, in people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this combination works better than the standard available treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma that has come back or not responded to treatment.
- You must have had between 1 and 4 previous treatments for myeloma, including both a CD38-targeted drug (like daratumumab or isatuximab) and lenalidomide.
- Your myeloma must be measurable with standard blood or urine tests.
- You must be physically able to do daily activities (ECOG performance status 0-2).
- You must have adequate kidney, liver, and blood counts as confirmed by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called inobrodib combined with two standard treatments (pomalidomide and dexamethasone) for people whose multiple myeloma has come back or did not respond. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
This trial tests a new combination of three drugs (belantamab mafodotin, cevostamab, and pomalidomide) for patients with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if this combination is safe and effective.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.